Stock GLTO GALECTO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Galecto, Inc.

Equities

GLTO

US36322Q1076

Delayed Nasdaq
Other stock markets
 11:33:54 2024-05-02 am EDT 		5-day change 1st Jan Change
0.705 USD +3.67% Intraday chart for Galecto, Inc. +5.41% -2.07%
May. 01 Galecto, Inc. Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab CI
Apr. 29 Galecto, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab
AQ
Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis
AQ
GALLANT-1: GB1211 Galectin-3 (Gal-3) inhibitor plus atezolizumab (atz) for first line treatment in patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC)
PU
Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial
AQ
Galecto Announces Plans to Explore Strategic Alternatives
AQ
Galecto to Present at Investor Conferences in September
AQ
Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis
AQ
Galecto Reports Second Quarter Operating and Financial Results
AQ
Galecto Set to Join Russell Microcap® Index
AQ
Galecto to Present at the Upcoming Jefferies Healthcare Conference
AQ
Galecto Completes Dosing in 52-Week Phase 2b GALACTIC-1 Trial of GB0139 in Idiopathic Pulmonary Fibrosis
AQ
Galecto : ATS 2023 poster - The Anti-Fibrotic Effect of GB0139, a Small Molecule Galectin-3 Inhibitor, in Precision Cut Lung Slices from Idiopathic Pulmonary Fibrosis Tissue
PU
Galecto to Present Poster at Upcoming ATS 2023 International Conference
AQ
Galecto Reports First Quarter Operating and Financial Results
AQ
GALECTO, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
Galecto to Present Two Posters at AACR Annual Meeting 2023
AQ
GALECTO, INC. : Regulation FD Disclosure (form 8-K)
AQ
Galecto Reports Operating and Financial Results for the Year Ended December 31, 2022
GL
Galecto Reports Operating and Financial Results for the Year Ended December 31, 2022
GL
GALECTO, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GLTO Stock
  4. News Galecto, Inc.
  5. Press Releases